Protalix Biotherapeutics, Inc. is a US-based pharmaceutical company specializing in developing and commercializing recombinant therapeutic proteins using its innovative ProCellEx system. They have successfully created treatments for various rare diseases such as Gaucher disease, Fabry disease, and cystic fibrosis. With an ESG score of 28.2, Protalix Biotherapeutics is classified as a medium-risk firm. Their revenue streams include sales of BioManguinhos alfataliglicerase in Brazil and supplying drug substances to Pfizer. Notable products in their pipeline include ELFABRIO, Uricase, and Long Acting DNase I.